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Until relatively recently, long-acting injectable (LAI) 
formulations were only available for first-generation 
antipsychotics and their utilization decreased as use of 
oral second-generation antipsychotics (SGA) increased. 
Although registry-based naturalistic studies show LAIs 
reduce rehospitalization more than oral medications 
in clinical practice, this is not seen in recent random-
ized clinical trials. PROACTIVE (Preventing Relapse 
Oral Antipsychotics Compared to Injectables Evaluating 
Efficacy) relapse prevention study incorporated efficacy 
and effectiveness features. At 8 US academic centers, 305 
patients with schizophrenia or schizoaffective disorder were 
randomly assigned to LAI risperidone (LAI-R) or physi-
cian’s choice oral SGAs. Patients were evaluated during 
the 30-month study by masked, centralized assessors using 
2-way video, and monitored biweekly by on-site clinicians 
and assessors who knew treatment assignment. Relapse 
was evaluated by a masked Relapse Monitoring Board. 
Differences between LAI-R and oral SGA treatment in 
time to first relapse and hospitalization were not signifi-
cant. Psychotic symptoms and Brief Psychiatric Rating 
Scale total score improved more in the LAI-R group. In 
contrast, the LAI group had higher Scale for Assessment 
of Negative Symptoms Alogia scale scores. There were no 
other between-group differences in symptoms or functional 
improvement. Despite the advantage for psychotic symp-
toms, LAI-R did not confer an advantage over oral SGAs 
for relapse or rehospitalization. Biweekly monitoring, not 
focusing specifically on patients with demonstrated non-
adherence to treatment and greater flexibility in changing 
medication in the oral treatment arm, may contribute to 
the inability to detect differences between LAI and oral 
SGA treatment in clinical trials.
Key words: relapse prevention/schizophrenia/psychotic 
symptoms/negative symptoms/clinical trial design
Introduction
Relapse prevention remains a major public health chal-
lenge in schizophrenia treatment. Symptom exacerbations 
increase personal suffering, psychosocial deterioration, 
family/societal burden, risk of harm to self  and others, 
and impair progress toward recovery.1–3 It has even been 
suggested that repeated relapses are neurotoxic, aggravat-
ing the long-term course of illness.1
There is ample evidence that antipsychotic medica-
tion substantially reduces relapse risk.1–3 However, even 
partial nonadherence to oral medications may erode 
this potential benefit.2,4 Delivery of continuous, assured 
medication through long-acting injectable (LAI) antipsy-
chotic formulations has a long history of use to minimize 
nonadherence.2,3 This potential clinical effect is not phar-
macodynamic although there may be pharmacokinetic 
advantages based on lower and less variable plasma con-
centrations with LAI administration.3 The primary role 
of LAIs in relapse reduction is pragmatic. Once admin-
istered, there is no risk of missed daily doses, and if  a 
patient fails to appear for a scheduled injection, clinicians 
are immediately aware of nonadherence well before any 
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possible consequences. In contrast, patients may fail to fill 
oral medication prescriptions or report that they are tak-
ing medication when they are either partially or entirely 
nonadherent.4 Unfortunately, clinicians have difficulty in 
detecting these behaviors and tend to overestimate adher-
ence in their patients.3,4
Although many support the face validity of  assump-
tions regarding LAI superiority, there are disparate find-
ings in both early studies with FGAs and more recent 
studies that investigate SGAs. Leucht and colleagues5 
reported a 30% reduction in relapse rate favoring LAI 
over oral medications; this meta-analysis drew on stud-
ies stretching back 40  years, and most compared first-
generation antipsychotics (FGA) oral and LAIs. They 
also reported that studies that targeted relapsing patients 
with confirmed nonadherence showed the most robust 
differences. There was a 14-year hiatus between the last 
studies with FGA LAIs and the first studies with sec-
ond-generation antipsychotics (SGA) LAIs. A  recent 
meta-analysis in this journal by Kishimoto and col-
leagues6 failed to find advantages for LAIs in general, 
but fluphenazine decanoate stood out as more effective 
than oral FGA medications. The finding of  fluphenazine 
decanoate superiority may be a function, the time that 
the studies were done (1970s) when the only medications 
available were FGAs and therefore all used oral FGA 
comparators. Another meta-analysis of  19 studies pub-
lished between 2000 and 2011 found no difference over-
all between LAI and oral medications.7 Kishimoto and 
colleagues8 also reported an overall relapse rate of  37% 
among patients receiving either oral or LAI formula-
tions of  FGAs, while the relapse rate on SGAs (predomi-
nately studies of  oral SGAs) was 29%. In a most recent 
evaluation of  mirror-image studies, LAIs were superior 
over oral medications with respect to reducing hospital-
ization.9 Disparate findings across studies and over time 
might reflect real drug differences and/or be accounted 
for by patient selection biases and methodological varia-
tions. Such variances have historically hampered clinical 
interpretation as to the most apt positioning of  LAIs in 
our clinical armamentarium.
PROACTIVE (Preventing Relapse Oral Antipsychotics 
Compared to Injectables Evaluating Efficacy) was initiated 
in 2006 to inform clinical decision making by conducting 
an up-to-date relapse prevention study that included both 
efficacy/explanatory and effectiveness/pragmatic fea-
tures. Table 1 presents study characteristics that highlight 
these considerations. LAI-R was selected because it was 
the only SGA LAI available in 2006. Historically, while 
LAI-oral comparative studies with FGAs showed similar 
patterns of relapse in a first year of treatment,2 possible 
differences in relapse rates emerged in the second year.10 
Treatment in PROACTIVE lasted for up to two and half  
years, included patients who were within a year of prior 
relapse, and was multisite. This article focuses on relapse, 
rehospitalization, and symptom change.
Methods
Patients with a Diagnostic and Statistical Manual of 
Mental Disorders IV-TR diagnosis of schizophrenia or 
schizoaffective disorder11 were enrolled at 8 US academic 
centers and, after providing informed consent and com-
pleting baseline assessments, were randomly assigned to 
receive either LAI-R or physician’s choice of oral SGA 
medication. Inclusion criteria included age between 
18–65 years, symptom exacerbation within 12 months of 
screening but community dwelling for at least 4 weeks, at 
least moderately ill (Clinical Global Impressions [CGI] 
severity score of four or greater), and able to provide writ-
ten informed consent. Exclusion criteria included first 
episode of psychosis, allergy to risperidone, inadequate 
prior response to risperidone, treatment-refractoriness 
and/or lack of response to clozapine, or medical instabil-
ity. Pregnant or lactating women were excluded. Receipt 
of an LAI was not an exclusion criterion; patients could 
be randomized to either LAI-R or oral medication. If  
randomized to LAI-R and receiving a FGA LAI, they 
Table 1. Comparison of Efficacy/Explanatory and Effectiveness/Pragmatic Clinical Trials
Domain Effectiveness/Pragmatic Trial Efficacy/Explanatory Trial
Participant eligibility “All comers” Limited to select, well-defined study 
population
Experimental intervention Flexibility in implementation Clearly delineated and rigorously followed
Comparison intervention Usual practice Clearly defined, often placebo condition 
rather than clinically driven choice
Companion intervention  
clinician expertise
Accommodates clinical styles in 
implementation
Rigidly applied to minimize  
clinician impact
Outcome Clinically meaningful Direct consequence of intervention
Adherence No explicit measurement Measured; might be exclusionary criterion
Clinician adherence to protocol Effectiveness not monitored Efficacy closely monitored
Analysis of primary outcome Inclusive of all patients Intention-to-treat
Source: Adapted from Thorpe et al.25
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were switched to LAI-R. If  randomized to oral, the LAI 
was discontinued and an oral SGA was initiated. The 
study (clinicaltrials.gov NCT00330863) was approved 
by Institutional Review Boards at all sites. Study con-
duct and safety were monitored by a National Institute 
of Mental Health, Data and Safety Monitoring Board. 
It was conducted between August 2006 and January 
2011. Study duration was up to 30 months for the 68% 
of subjects enrolled by July 2008; for those subsequently 
enrolled, duration was between 17 and 29 months.
Study Medications
Following randomization, medication was administered 
openly, guided by an evidence-based Medication Manual 
developed by the investigators (available upon request). 
Subjects were seen biweekly; LAI-R subjects received 
injections, and Oral SGA subjects received a 2-week medi-
cation supply. Antipsychotic medications, provided by the 
manufacturers, were cost-free. We assessed adherence at 
biweekly visits. Subjects who missed scheduled appoint-
ments received follow-up reminders, but study staff  did 
provide treatment in the community. Antipsychotic 
polypharmacy was discouraged. Mood stabilizers and/
or antidepressant medications prescribed prior to ran-
domization were continued. Anticholinergic medication 
was permitted for extrapyramidal side effects (benztro-
pine mesylate preferred), and propranolol was recom-
mended for akathisia. Insomnia could be treated with 
hypnotic agents (including benzodiazepines) or low dose 
quetiapine up to 200 mg/d). LAI-R was initiated with a 
25-mg injection. Oral antipsychotic medication was con-
tinued for at least 3 weeks before tapering with the goal 
of completing cross-titration within 6 weeks. Injection 
dosage could be increased as needed to 37.5 or 50 mg or 
reduced to 12.5 mg. Subjects receiving a FGA LAI were 
switched to LAI-R and did not receive oral supplementa-
tion. Most subjects received gluteal injections, alternating 
sides. If  symptoms worsened, dose increases of LAI-R 
were recommended. Oral risperidone supplementation 
was allowed to manage symptom exacerbation.
Subjects randomized to oral SGAs continued the oral 
SGA they were receiving or, if  they were not receiving an 
oral SGA, any marketed oral SGAs could be selected. 
These included aripiprazole, olanzapine, quetiapine, ris-
peridone, and ziprasidone at study initiation. Paliperidone, 
asenapine, and iloperidone were added upon Food and 
Drug Administration (FDA) approval. If  subjects were 
receiving an LAI, it was discontinued and an oral SGA 
initiated. Oral antipsychotics could be changed based on 
lack of efficacy, side effects, or patient preference.
Assessment
Chart diagnosis was confirmed by diagnostic case con-
ferences, led by the site Principal Investigator. Subjects 
were assessed by on-site clinical raters and study psy-
chiatrists biweekly for medication adherence, vital signs, 
symptoms, and side effects. Symptoms were assessed 
with an abbreviated version of  the Brief  Psychiatric 
Rating Scale (BPRS)12; items included grandiosity, sus-
piciousness, unusual thought content, hallucinatory 
behavior, conceptual disorganization, mannerisms and 
posturing, blunted affect and emotional withdrawal, 
and the CGI.13 Use of  services including hospitaliza-
tion, emergency room visits, and crisis intervention 
was recorded. Quarterly visits included the full BPRS, 
CGI, the Scale for Assessment of  Negative Symptoms 
(SANS),14 the Scale of  Functioning (SOF),15 the 
Abnormal Involuntary Movement Scale,16 the Barnes 
Akathisia Scale,17 the Simpson-Angus Scale,18 a modi-
fied sexual side effects questionnaire,19 and the New 
Antipsychotics Metabolic Evaluation Scale.20 Fasting 
blood chemistry, glucose, cholesterol, and lipid profiles 
were evaluated quarterly. The BPRS, SANS, and CGI 
were completed by 2 “Master Raters.” The first, at The 
Zucker Hillside Hospital, was an MSW with extensive 
experience in completing these rating scales and training 
others to do so. In addition to completing assessments, 
she trained all site raters. The second, at the University 
of  Iowa, was a research coordinator with many years 
of  researcher assessment experience. They interviewed 
subjects using a live, 2-way video connection and were 
masked to treatment assignment. These highly experi-
enced clinical assessors provided the standard for train-
ing and reliability and completed all assessments during 
the 5-year study. Interrater reliability was excellent, with 
intraclass correlations (ICC) of  0.75 between the Master 
Raters, ICC of  0.79 between site and Master Raters, and 
ICC of  0.75 among site raters.
Primary Outcome
Relapse, adapted from criteria first used by Csernansky 
and colleagues,21 was defined by (1) psychiatric hospital-
ization for worsening symptoms but not for social reasons; 
(2) increase in level of psychiatric care (eg, significant cri-
sis intervention to avert hospitalization, emergency room 
visit, increase in frequency of contact to maintain outpa-
tient status); (3) substantial clinical deterioration as indi-
cated by a score of 6 (much worse) or 7 (very much worse) 
on the CGI-I scale, or a sustained increase in psychotic 
symptoms as rated by either site or the Master Rater; and 
(4) deliberate self-injury, suicidal or homicidal ideation 
that was judged clinically significant as determined by 
the investigator, violent behavior resulting in clinically 
significant injury to another person or property damage. 
Time of first and subsequent relapses was independently 
evaluated by a Relapse Monitoring Board (RMB) of 
schizophrenia experts, masked to treatment assignment. 
The RMB also identified less severe episodes of symp-
tom exacerbation defined by substantial and sustained 
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increases in psychotic symptoms that lasted at least 4 
weeks (3 biweekly visit ratings).
Secondary Outcomes
Relapse did not require discontinuation of treatment or 
study participation. Reasons for treatment discontinua-
tion included discontinuation of LAI-R in the injectable 
arm, receipt of a LAI in the oral arm, or receipt of clo-
zapine in both. Subjects who discontinued randomized 
treatment continued to be assessed quarterly. Reasons for 
study discontinuation included serious and/or life-threat-
ening adverse event (AE); serious and/or life-threatening 
clinical circumstances (eg, uncontrollable violence or 
suicidal behavior and/or severe relapse); withdrawal of 
consent; loss to follow-up; serious protocol violation; or 
administrative reasons.
Symptom and functioning measures included BPRS, 
SANS, and CGI ratings by the Master Raters, and SOF 
ratings by on-site raters.
Statistical Analysis
Subjects randomly assigned to treatment who received 
at least one dose of medication (LAI-R injection or oral 
prescription) were included in intent-to-treat analyses. 
The primary outcome was time to first relapse compared 
between the 2 groups by Kaplan-Meier survival analysis.21 
Time to first hospitalization was also compared between 
groups. Secondary outcome measures included psychotic 
symptoms, other psychiatric symptoms, social function-
ing, and adverse effects.
BPRS measures and SANS affective flattening and alo-
gia were highly positively skewed and were analyzed using 
generalized linear mixed model regression analyses with 
lognormal error distribution (SAS GLIMMIX, Version 
9.2). Supplemental analyses specifying gamma-distributed 
error were very similar. SANS avolition-apathy and asoci-
ality-anhedonia, the CGI severity and improvement, and 
the 2 SOF variables were reasonably symmetric-unimodal 
and were analyzed using general linear mixed effects 
regression models that assumed normally distributed 
error (SAS MIXED, Version 9.2).22 Both statistical pro-
cedures assume data are missing at random. Mixed effects 
regression models used data after baseline, with baseline 
values as a covariate (except for CGI improvement). Fixed 
design effects were treatment, visit, and their interaction. 
First-degree autoregressive structure (AR1) was specified 
for the covariance matrices (up to ten post-baseline mea-
sures), and a random subject effect was included to model 
between-subject variability.23 Statistical significance was 
set at unadjusted 2-tailed P = .05.
Results
Figure 1 shows that 305 subjects were randomly assigned 
to treatment; 153 to LAI-R and 152 to Oral SGAs. Seven 
LAI-R subjects and 2 Oral SGA subjects received no 
medication after randomization and were not included in 
comparative analyses. At study entry, 276 patients were 
receiving antipsychotic medication; 29 were not. SGAs 
were received by 255 with risperidone most frequent (125). 
Seventy-one were receiving more than 1 antipsychotic; 32 
were receiving an LAI antipsychotic; R-LAI 22, FGA 
LAI 10. Table 2 shows baseline subject characteristics by 
treatment group. Study subjects were on average 38 years 
old; 71% were male. Although age at first episode (23) and 
number of psychiatric hospitalizations (11) were compa-
rable, LAI-R subjects had been hospitalized more recently 
(mean 22.4 months ago) than Oral SGA subjects (mean 
40.4 months ago). Symptom ratings at baseline were com-
parable except for SANS Avolition/apathy, which was less 
severe in the Oral group and SOF scores that showed sig-
nificantly better functioning in the Oral group.
Mean treatment duration for subjects was 
551.2 ± 341.8  days for LAI-R (N = 146) and 
542.6 ± 335.4  days for Oral SGA (N = 150; t = .22, df 
= 294, P = .83). In the LAI-R group, the modal dose 
received was 50 mg (38%); 37.5 mg (22.%); 25 mg (22%); 
12.5 mg (6%); 62.5 mg (5%); 75 mg (5%). Seventy-four 
(30.4%) of LAI-R subjects received supplementation 
with oral antipsychotics after the initial transition period. 
For the Oral SGA group, risperidone was most frequently 
prescribed for 67 (44%); the mean (SD) of the modal pre-
scribed dose was 5.1 (2.1). Olanzapine was prescribed for 
30 (20%), mean (SD) dose of 23 (13.6); aripiprazole for 
22 (14%), mean (SD) dose 23.4 (10.6); ziprasidone for 
14 (9%), mean (SD) dose 142.8 (56.5); paliperidone for 
9 (6%), mean (SD) dose 8.3 (2.9); quetiapine for 8 (5%), 
mean (SD) dose 525 (138.9); and iloperidone 1 (1%) dose 
12. At study entry 26 (17.3%) changed from their prior 
antipsychotic medication. Further, during the course of 
study treatment, 43 (28%) had their oral antipsychotic 
changed. Concomitant psychotropic medications were 
used for 58% of LAI-R subjects and 61% of Oral SGA 
subjects. These included antidepressants—LAI-R 44% 
and Oral SGA 40%. mood stabilizers (18% and 20%), 
and anxiolytic/hypnotics (33% and 37%).
As shown in figure  1, 161 (53%) of subjects discon-
tinued treatment before study end (81 in LAI-R and 80 
in Oral SGA). Reasons for discontinuation were subject 
decision (LAI-R 21, Oral 12); clinical decision LAI-R 
29, Oral 19); intervening illness or other administrative 
(LAI-R 17, Oral 28); lost to follow-up (LAI-R 12, Oral 
18); and deceased (LAI-R 2, Oral 3). Overall 109 subjects 
(37%) experienced a relapse; 61/146 (42%) in the LAI-R 
group and 48/150 (32%) in the Oral SGA group (χ in 
the df = 1, P = .08). There was no significant difference 
between groups in time to first relapse (log rank χ, P = 
.08, df = 1, P = .13) or first hospitalization (log rank χ= 1, 
P = df = 1, P = .30; figure 2).
In between-group comparisons on the BPRS, SANS, 
CGI, and SOF (see supplementary tables), there were 
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significant differences favoring LAI-R in the BPRS total 
score averaged over time (treatment F = 4.17, df = 1, 274, 
P = .042, Cohen’s d = 0.25; visit F = 8.25, df = 9, 1264, P 
< .0001; treatment × visit F = 0.70, df = 9, 1264, P = .71). 
Similar improvement over time, particularly in the second 
year, was observed favoring LAI-R for BPRS psychosis 
cluster (treatment F = 5.24, df = 1, 285, P = .023, Cohen’s 
d = 0.27; visit F = 5.36, df = 9, 1295, P < .0001; treatment 
× visit F = 2.35, df = 9, 1295, P = .013). There were no 
significant differences between treatments for the remain-
ing BPRS symptom clusters of anxiety-depression, nega-
tive symptoms, and excitement. There was a significant 
difference favoring Oral SGA on SANS alogia (F = 4.46, 
df = 1, 279, P = .036, Cohen’s d = 0.25). Treatment dif-
ferences on the other 3 SANS global ratings (affective 
flattening, avolition, asociality-anhedonia), CGI severity 
and improvement, and the 2 SOF measures (total score 
and global rating) were not significant.
Fig. 1. Patient randomization, completion, and discontinuation rates in relapse prevention study of long-acting injectable (risperidone 
microspheres) and second-generation antipsychotic oral medications. *Full study period ranged between 17 and 30 months, depending 




Six subjects died during the study, 2 in the LAI-R group 
(1 with apparently unrelated renal failure, 1 from sui-
cide) and 4 in the Oral SGA group (1 from suicide, 1 due 
to unintentional illicit drug overdose, 1 unknown cause, 
and 1 of  cardiac arrest after treatment exit). Table  3 
presents treatment emergent AEs by treatment group. 
The table shows the most severe rating received for each 
AE. AE severity was low; the mean rating is less than 
2 (mild) for all AEs in both groups. There was 1 sta-
tistically significant difference between groups; anorexia 
was lower in the Oral than the LAI-R arm. Two trend 
Table 2. Baseline Characteristics of PROACTIVE Study Participants
Variable Total (n = 305) LAI-R (n = 153)
Oral Second-Generation 
Antipsychotics (n = 152)
Test and Significance of 
Difference
Age (mean/SD) 38.2 ± 12.1 38.18 ± 11.8 38.32 ± 12.3 t = 0.10, df = 303, P = .92
Gender (%)
 Male 218 (71%) 108 (71%) 110 (72%) χ2 = 0.12, df = 1, P = .73
 Female 87 (29%) 45 (29%) 42 (28%)
Diagnosis (%)
 Schizophrenia NOS 5 (2%) 4 (3%) 1 (1%) χ2 = 1.3, df = 3, P = .74 
(NOS, residual excluded)
 SZ disorganized 23 (8%) 11 (7%) 12 (8%)
 SZ paranoid 123 (40%) 66 (43%) 57 (38%)
 SZ residual 1 (0.3%) 0 (0%) 1 (1%)
 Schizoaffective 99 (32%) 46 (30%) 53 (35%)
 SZ undifferentiated 54 (18%) 26 (17%) 28 (18%)
Age at first hospitalization 
(Mean/SD)
22.8 ± 8.8 (N = 283) 23.0 ± 9.2 (N = 143) 22.6 ± 8.4 (n = 140) t = 0.41, df = 281, P = .68
Number of hospitalizations 
(including current, mean/SD)a
10.9 ± 34.4 (N = 281) 12.0 ± 46.0 (N = 138) 9.9 ± 17.2 (N = 143) t = 0.50, df = 279, P = .62
Time (in months) since last 
hospitalization (mean/SD)b
31.5 ± 64.3 (N = 269) 22.4 ± 35.9 (N = 133) 40.4 ± 82.4 (N = 136) t = 2.31, df = 267, P = .021
Racial distribution (%)
 Caucasian 159 (52%) 81 (53%) 78 (51%) χ2 = 0.6, df = 2, P = .75 
(Other excluded)
 African American 85 (28%) 45 (29%) 40 (26%)
 Hispanic 58 (19%) 27 (18%) 31 (20%)
 Other 3 (1%) 0 (0%) 3 (2%)
Educational level (%)
 Some college or above 130 (43%) 66 (45%) 64 (42%) χ2 = 0.3, df = 2, P = .87
 High school graduate 82 (27%) 40 (27%) 42 (28%)
 Below high school 87 (29%) 41 (28%) 46 (30%)
Employed at study entry (%) 48 (16%) (N = 297) 23 (16%) (N = 148) 25(17%) (N = 149) χ2 = 0.1, df = 1, P = .77
Clinical Global Impressions
 Severity 4.04 ± 0.80 4.1 ± 0.84 4.0 ± 0.77 t = 0.78, df = 303, P = .44
Brief  Psychiatric Rating Scale
 Total 38.1 ± 9.32 38.2 ± 9.53 38.0 ± 9.13 t = 0.21, df = 302, P = .83
 Psychosis cluster 2.7 ± 1.09 2.7 ± 1.12 2.7 ± 1.08 t = −0.03, df = 303, P = .97
 Anxiety/depression 2.8 ± 0.99 2.8 ± 1.06 2.8 ± 0.91 t = 0.23, df = 303, P = .82
 Negative signs/symptoms 1.6 ± 0.66 1.6 ± 0.67 1.6 ± 0.65 t = 0.66, df = 301, P = .51
 Excitement/activation 1.4 ± 0.56 1.4 ± 0.56 1.4 ± 0.56 t = −0.09, df = 301, P = .93
Scale for Assessment of Negative Symptoms
 Affective flattening 1.9 ± 0.97 1.9 ± 0.97 1.9 ± 0.97 t = −0.29, df = 303, P = .77
 Alogia 1.4 ± 0.78 1.4 ± 0.71 1.4 ± 0.84 t = −0.47, df = 303, P = .64
 Avolition/apathy 3.2 ± 1.10 3.4 ± 1.03 3.0 ± 1.14 t = 2.68, df = 303, P = .008
 Asociality/anhedonia 3.2 ± 0.93 3.3 ± 0.93 3.2 ± 0.93 t = 1.43, df = 301, P = .15
Scale of Functioningb
 Sum of items 1–14 40.9 ± 7.26 40.1 ± 7.24 41.8 ± 7.19 t = −2.07, df = 300, 
P = .040
 Global rating (Item 15)b 2.7 ± 0.71 2.7 ± 0.68 2.8 ± 0.73 t = −2.00, df = 300, 
P = .047
Note: LAI-R, long-acting injectable risperidone; NOS, not otherwise specified; SZ, schizophrenia.
aWilcoxson Rank-Sum test, P = .84; t test excluding outlier: t = 0.96, df = 278, P = .34; Poisson regression, P = .69.





Fig. 2. A comparison of time to first relapse (a) between patients receiving either long-acting injectable risperidone (LAI-R) or oral 
second-generation antipsychotics medications (b) and first hospitalization.
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level differences (blurred vision and sedation/drowsi-
ness) favored LAI-R.
Discussion
We did not find a significant difference between schizo-
phrenia subjects randomized to LAI-R or oral SGA 
medications in either time to relapse or hospitalization 
in a study that incorporated both explanatory and prag-
matic design features. Controlling for time since last hos-
pitalization, which was longer in the Oral SGA group, 
did not alter this finding. In contrast, increasing over the 
30-month study course, we observed a more robust reduc-
tion in psychotic symptoms among patients who received 
the LAI formulation.
Following initial establishment of safety and efficacy 
in FDA-mandated registration trials, our field has shifted 
toward more pragmatic clinical trials in the belief  that 
these may provide greater real-world generalizability 
than traditionally highly restrictive randomized, dou-
ble-blind, placebo controlled studies.24,25 PROACTIVE 
had both efficacy/explanatory and effectiveness/prag-
matic design features. We balanced the methodological 
rigor of explanatory trials (randomization to treatment, 
expert clinical care, and uniform, frequent monitoring), 
with pragmatic features (broad clinical representation, 
physician’s choice of treatment within the oral treatment 
arm, open clinical care following randomization, flexible 
dosing, and continued participation after experiencing a 
relapse). Consistent with an explanatory design, all sub-
jects in the trial were seen every 2 weeks (as were those 
in many other studies), and both R-LAI and oral anti-
psychotic medications were provided. Frequent clinical 
contact might reduce relapse in both groups and reduce 
power to detect between-group differences. This effect 
could be a function of the supportive effects of clinical 
contacts, enhanced medication adherence monitoring, 
and the direct provision of oral medication, eliminating 
the need to fill prescriptions.2 Further, our patient popu-
lation was not selected for documented nonadherence to 
medication, and requirements for informed consent to 
randomization to an LAI may have reduced the inclusion 
of these participants. Because the hypothesized advan-
tage of LAIs is driven by enhanced medication adherence 
and detection of nonadherence, selection of patients who 
are more engaged in their care and therefore less likely to 
stop taking oral medication could make it more difficult 
to detect differences between LAI and oral treatment.2
PROACTIVE replicates and extends the results of a 
study with similar design in the VA population, largely con-
fined to men. Rosenheck and colleagues26 reported hospital-
ization rates of 39% and 45%, respectively, among patients 
Table 3. Adverse Events Most Severe Level Recorded After Baseline by Treatment (Mean ± SD)
Adverse Event Total (n = 291)a LAI-R (n = 143)
Oral Second-Generation 
Antipsychotics (n = 148)
Test and Significance of 
Difference
Bruising easily 1.45 ± 0.71 1.43 ± 0.67 1.48 ± 0.75 t = −0.64, P = .52
Rash 1.48 ± 0.74 1.53 ± 0.78 1.44 ± 0.71 t = 1.06, P = .29
Urticaria (hives, itching) 1.66 ± 0.77 1.60 ± 0.69 1.71 ± 0.84 t = −1.20, P = .23
Blurred vision 1.84 ± 0.79 1.76 ± 0.73 1.91 ± 0.83 t = −1.63, P = .10
Sedation/drowsiness 2.43 ± 0.83 2.34 ± 0.87 2.53 ± 0.78 t = −1.90, P = .058
Restlessness 2.45 ± 0.79 2.48 ± 0.76 2.43 ± 0.82 t = 0.47, P = .64
Insomnia 2.37 ± 0.92 2.38 ± 0.89 2.36 ± 0.94 t = 0.18, P = .86
Malaise (weakness, fatigue) 2.18 ± 0.86 2.22 ± 0.85 2.14 ± 0.87 t = 0.75, P = .46
Stiffness 1.99 ± 0.84 2.01 ± 0.82 1.97 ± 0.85 t = 0.49, P = .63
Tremor 1.76 ± 0.76 1.77 ± 0.72 1.75 ± 0.80 t = 0.22, P = .83
Dizziness 1.80 ± 0.81 1.82 ± 0.79 1.78 ± 0.82 t = 0.43, P = .66
Headache 1.94 ± 0.89 1.99 ± 0.88 1.89 ± 0.90 t = 1.04, P = .30
Fever 1.25 ± 0.47 1.27 ± 0.49 1.24 ± 0.46 t = 0.53, P = .60
Sore throat 1.60 ± 0.74 1.64 ± 0.78 1.57 ± 0.69 t = 0.72, P = .47
Dry mouth 2.31 ± 0.93 2.36 ± 0.92 2.25 ± 0.94 t = 1.04, P = .30
Hypersalivation 1.80 ± 0.87 1.76 ± 0.80 1.84 ± 0.94 t = −0.74, P = .46
Enuresis 1.59 ± 0.86 1.63 ± 0.89 1.56 ± 0.83 t = −0.68, P = .50
Constipation 1.69 ± 0.84 1.75 ± 0.86 1.64 ± 0.82 t = 1.08, P = .28
Diarrhea 1.66 ± 0.83 1.65 ± 0.86 1.68 ± 0.81 t = −0.26, P = .80
Anorexia (loss of appetite) 1.77 ± 0.85 1.89 ± 0.86 1.69 ± 0.84 t = 2.00, P = .046
Nausea 1.75 ± 0.81 1.78 ± 0.82 1.72 ± 0.80 t = 0.70, P = .48
Vomiting 1.49 ± 0.74 1.48 ± 0.72 1.51 ± 0.76 t = −0.44, P = .66
Menstrual irregularity (N = 122) 1.58 ± 0.91 1.62 ± 0.96 1.55 ± 0.86 t = 0.41, df = 120, P = .68
Breast tenderness/galactorrhea 
(N = 290)
1.36 ± 0.65 1.39 ± 0.69 1.32 ± 0.61 t = 0.91, df = 288, P = .36
Note: LAI-R, long-acting injectable risperidone. Only subjects with postbaseline ratings are included.
aN = 291 (LAI-R: 143, Oral second-generation antipsychotics: 148), all t tests have df = 289 except as noted.
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receiving LAI-R and oral SGA medications during a 2-year 
follow-up. This study, with a broader patient population, 
confirms the absence of a statistically significant difference 
between LAI and oral medications in preventing relapse 
and rehospitalization but does identify improvement over 
time in psychotic symptoms with LAI treatment.
Other recent studies using hospitalization or even 
broader criteria of relapse report similar outcomes: 46% 
relapse rate for LAI-R vs 43% for oral aripiprazole.27 
A  recent 2-year trial of LAI olanzapine and oral olan-
zapine reported similar relapse rates for both treatment 
groups (20% for LAI, 18% for oral) although patients 
receiving LAI olanzapine spent less time in hospital 
when they relapsed.28 A significant advantage for LAI-R 
(16%) was found compared with quetiapine (31%)29; and 
in the same study a numerical “descriptive” advantage 
compared with aripiprazole (27%).30 In a recent study of 
LAI-R risperidone vs oral quetiapine, Smeraldi and col-
leagues reported similar remission rates among patients 
in both treatment groups.31 In a post-hoc analysis of tri-
als comparing LAI paliperidone to oral paliperidone, the 
risk of relapse was greater among patients receiving oral 
medications.32 Collectively, the results of modern-day 
LAI-oral comparisons are mixed. Moreover, as reviewed 
in the “Introduction” section, meta-analyses undertaken 
to clarify “the signal” from studies over time have added 
to the confusion and convey the overall impression of 
minimal (or perhaps, if  any, only targeted) advantage for 
LAIs as a part of our clinical armamentarium.
One reason that overall 30-month relapse rate was 
relatively low (37%) may be the biweekly clinic visits, 
designed to match the timing of injections with LAI-R. 
This frequency is higher than current practice, and if  it 
were an appropriate evidence-based standard of care, 
it could overwhelm an already burdened community 
mental health services system. However, there are ways 
to increase contact that do not require in-person clinic 
visits.33–35 A  rigorous scientific evaluation of optimum 
frequency and model(s) of contact and interaction with 
follow-up and continuity of outpatient care for schizo-
phrenia patients would be an important and timely 
contribution.
The timing of introduction of LAI treatment during 
the course of illness may also be important in understand-
ing the role LAIs in the treatment of schizophrenia. Most 
studies that compared LAIs and oral medications have 
been in patients with chronic schizophrenia. A recent US 
study of LAI in first-episode schizophrenia patients36,37 
and a European pharmacoepidemological study of LAI 
and oral antipsychotic medications used following initial 
hospitalization for schizophrenia38 raise the possibility 
that introduction of LAIs early in the course of illness 
might be advantageous. Other study models may also be 
useful in clarifying the role of LAIs. For example, a large, 
simple trial has never been conducted utilizing LAIs. This 
would entail randomization to LAI vs oral antipsychotic 
with no other “research” contacts or assessments and 
with a readily observed outcome such as hospitalization. 
Further possibilities include studies that focus on specific 
patient groups, such as those who are currently experienc-
ing symptom exacerbation or have documented cognitive 
challenges in taking oral medications.
In conclusion, this was a relapse prevention trial with 
rigorous and innovative methods that incorporated a 
hybrid explanatory-pragmatic design. We found no sig-
nificant differences in relapse or hospitalization between 
LAI-R and oral SGA medications. However, there was a 
symptomatic advantage in psychosis severity for patients 
who were treated with LAI-R, particularly over longer 
course of study treatment. Given the enormous personal 
suffering, family burden, disruption in functioning, and 
societal cost associated with preventable relapse and 
rehospitalization, this remains an important area of study.
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